- Molecular NameIbutilide
- SynonymIbutilida [INN-Spanish]; Ibutilide; Ibutilide Fumarate; Ibutilidum [INN-Latin]
- Weight384.585
- Drugbank_IDDB00308
- ACS_NO122647-31-8
- Show 3D model
- LogP (experiment)5.756
- LogP (predicted, AB/LogP v2.0)4.79
- pka8.4, 9.6
- LogD (pH=7, predicted)1.85
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-2.59
- LogSw (predicted, AB/LogsW2.0)0.12
- Sw (mg/ml) (predicted, ACD/Labs)0.04
- No.of HBond Donors2
- No.of HBond Acceptors5
- No.of Rotatable Bonds14
- TPSA78.02
- StatusFDA approved
- AdministrationIntravenous
- PharmacologyA Class III antiarrhythmic agent that is indicated for acute cardioconversion of atrial fibrillation and atrial flutter of a recent onset to sinus rhythm. It exerts its antiarrhythmic effect by induction of slow inward sodium current, which prolongs action potential and refractory period (physiology) of myocardial cells.
- Absorption_value82.0
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability8.0
- Protein binding40.0
- Volume of distribution (VD)9 to 13 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmPrimarily hepatic. Eight metabolites of ibutilide were detected in metabolic profiling of urine. These metabolites are thought to be formed primarily by o-oxidation followed by sequential b-oxidation of the heptyl side chain of ibutilide. Of the eight metabolites, only the o-hydroxy metabolite possesses class III electrophysiologic properties similar to that of ibutilide in an in vitro isolated rabbit myocardium model.
- Half life6 h
- ExcretionRenal (82%), fecal
- Urinary ExcretionN/A
- Clerance29 ml/min/kg
- ToxicityAcute toxicity can cause potentially fatal arrhythmias, also tachycardia, hypotension, congestive heart failure, myocardial depression, third degree atrioventricular (AV) block and renal failure. Poison by intravenous route. Moderately toxic by ingestion.
- LD50 (rat)N/A
- LD50 (mouse)N/A